MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas

Modern Pathology

Volumn 23, Issue 12, 2010, Pages 1583-1595

  Tömböl, Zsófia ^a   Éder, Katalin ^b   Kovács, Attila ^a   Szabó, Peter M ^a   Kulka, Janina ^a   Likó, István ^c   Zalatnai, Attila ^a   Rácz, Gergely ^a   Tóth, Miklós ^a   Patócs, Attila ^b   Falus, András ^a,b   Rácz, Károly ^a   Igaz, Peter ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c GEDEON RICHTER LTD   (Hungary)

Author keywords

formalin fixed paraffin embedded; microRNA; multiple endocrine neoplasia type 2; pheochromocytoma; recurring; von Hippel Lindau disease

Indexed keywords

MICRORNA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MULTIPLE ENDOCRINE ADENOMATOSIS; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RECURRENCE; VON HIPPEL LINDAU DISEASE;

EID: 78649718773     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.164     Document Type: Article

References (47)

1. Weber F, Teresi RE, Broelsch CE, et al. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006;91: 3584-3591.
2. Tömböl Z, Szabó PM, Molnár V, et al. Integrative molecular bioinformatics study of human adrenocor-tical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 2009;16:895-906.
3. Opocher G, Schiavi F, Conton P, et al. Clinical and genetic aspects of phaeochromocytoma. Horm Res 2003;59:56-61.
4. Adler JT, Meyer-Rochow GY, Chen H, et al. Pheochro-mocytoma: current approaches and future directions. Oncologist 2008;13:779-793.
5. Goldstein RE, O'Neill JA, Holcomb GW, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229:755-766.
6. Karagiannis A, Mikhailidis DP, Athyros VG, et al. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 2007;14:935-956.
7. Babinska A, Sworczak K, Wisniewski P, et al. The role of immunohistochemistry in histopathological diagnostics of clinically 'silent' incidentally detected adrenal masses. Exp Clin Endocrinol Diabetes 2008;116:246-251.
8. van der Harst E, Bruining HA, Jaap Bonjer H, et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases- J Pathol 2000;191:175-180.
9. Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 2009;94:1541-1547.
10. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009;325: 1139-1142.
11. Dahia PL, Ross KN, Wright ME, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005;1:72-80.
12. Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-585.
13. Patocs A, Karadi E, Toth M, et al. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev 2004;13:403-409.
14. Gergics P, Patocs A, Toth M, et al. Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. Eur J Endocrinol 2009; 161:495-502.
15. Zhang X, Chen J, Radcliffe T, et al. An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 2008;10:513-519.
16. AACT method. Methods 2001;25:402-408.
17. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120: 15-20.
18. Enright AJ, John B, Gaul U, et al. MicroRNA targets in Drosophila. Genome Biol 2003;5:R1.
19. Szabo PM, Tombol Z, Molnar V, et al. MicroRNA target prediction: problems and possible solutions. Curr Bioinform 2010;5:81-88.
20. Papadopoulos GL, Alexiou P, Maragkakis M, et al. DIANA-mirPath: integrating human and mouse microRNAs in pathways. Bioinformatics 2009;25: 1991-1993.
21. Ribeiro-Silva A, Zhang H, Jeffrey SS. RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol Biol 2007;8, 118.
22. Liang Y, Ridzon D, Wong L, et al. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007;8, 166.
23. Doleshal M, Magotra AA, Choudhury B, et al. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2008;10: 203-211.
24. Siebolts U, Varnholt H, Drebber U, et al. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol 2009;62: 84-88.
25. Glud M, Klausen M, Gniadecki R, et al. MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J Invest Dermatol 2009;129: 1219-1224.
26. Nonn L, Vaishnav A, Gallagher L, et al. mRNA and micro-RNA expression analysis in laser-capture micro-dissected prostate biopsies: valuable tool for risk assessment and prevention trials. Exp Mol Pathol 2010;88:45-51.
27. Liu X, Chen Z, Yu J, et al. MicroRNA profiling and head and neck cancer. Comp Funct Genomics 2009;2009:837514.
28. Corbetta S, Vaira V, Guarnieri V, et al. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer 2010;17:135-146.
29. Guo J, Miao Y, Xiao B, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 2008;24: 652-657.
30. Hasseine LK, Hinault C, Lebrun P, et al. miR-139 impacts FoxO1 action by decreasing FoxO1 protein in mouse hepatocytes. Biochem Biophys Res Commun 2009;390:1278-1282.
31. Muiños-Gimeno M, Guidi M, Kagerbauer B, et al. Allele variants in functional microRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. Hum Mutat 2009;30:1062-1071.
32. Cavanaugh JE, Ham J, Hetman M, et al. Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 2001;21:434-443.
33. Du C, Yang DM, Zhang PX, et al. Neuronal differentiation of PC12 cells induced by sciatic nerve and optic nerve conditioned medium. Chin Med J 2010;123:351-355.
34. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-a miRNA microarray analysis. Genes Chromosomes Cancer 2009;48:615-623.
35. Lui WO, Chen J, Gläsker S, et al. Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome. Oncogene 2002;21: 1117-1122.
36. Edström E, Mahlamäki E, Nord B, et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol 2000;156:651-659.
37. Björklund P, Cupisti K, Fryknäs M, et al. Stathmin as a marker for malignancy in pheochromocytomas. Exp Clin Endocrinol Diabetes 2010;118:27-30.
38. Brouwers FM, Elkahloun AG, Munson PJ, et al. Gene expression profiling of benign and malignant pheo-chromocytoma. Ann NY Acad Sci 2006;1073:541-556.
39. Thouënnon E, Elkahloun AG, Guillemot J, et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab 2007;92:4865-4872.
40. Suh I, Shibru D, Eisenhofer G, et al. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. Ann Surg 2009;250:983-990.
41. Waldmann J, Fendrich V, Holler JP, et al. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocr Relat Cancer 2010;17:743-756.
42. Ju M, Selmaj K. Notch: a new player in MS mechanisms. J Neuroimmunol 2010;218:3-11.
43. Adler JT, Hottinger DG, Kunnimalaiyaan M, et al. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery 2008;144:956-961.
44. Yanamadala V, Negoro H, Denker BM. Heterotrimeric G proteins and apoptosis: intersecting signaling pathways leading to context dependent phenotypes. Curr Mol Med 2009;9:527-545.
45. Omura LA, Hong SM, Vincent A, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010;70:5226-5237.
46. Szafranszka AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adeno-carcinoma. Oncogene 2007;26:4442-4452.
47. Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006;13:497-508.